Communications Biology (Jun 2021)
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
- Andoni Garitano-Trojaola,
- Ana Sancho,
- Ralph Götz,
- Patrick Eiring,
- Susanne Walz,
- Hardikkumar Jetani,
- Jesus Gil-Pulido,
- Matteo Claudio Da Via,
- Eva Teufel,
- Nadine Rhodes,
- Larissa Haertle,
- Estibaliz Arellano-Viera,
- Raoul Tibes,
- Andreas Rosenwald,
- Leo Rasche,
- Michael Hudecek,
- Markus Sauer,
- Jürgen Groll,
- Hermann Einsele,
- Sabrina Kraus,
- Martin K. Kortüm
Affiliations
- Andoni Garitano-Trojaola
- Department of Internal Medicine II, University Hospital Würzburg
- Ana Sancho
- Department of Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg
- Ralph Götz
- Department of Biotechnology and Biophysics, Biocenter, University of Würzburg
- Patrick Eiring
- Department of Biotechnology and Biophysics, Biocenter, University of Würzburg
- Susanne Walz
- Comprehensive Cancer Center Mainfranken, Core Unit Bioinformatics, Biocenter, University of Wuerzburg
- Hardikkumar Jetani
- Department of Internal Medicine II, University Hospital Würzburg
- Jesus Gil-Pulido
- Institute of Molecular Biology
- Matteo Claudio Da Via
- Department of Internal Medicine II, University Hospital Würzburg
- Eva Teufel
- Department of Internal Medicine II, University Hospital Würzburg
- Nadine Rhodes
- Department of Internal Medicine II, University Hospital Würzburg
- Larissa Haertle
- Department of Internal Medicine II, University Hospital Würzburg
- Estibaliz Arellano-Viera
- Department of Internal Medicine II, University Hospital Würzburg
- Raoul Tibes
- Department of Internal Medicine II, University Hospital Würzburg
- Andreas Rosenwald
- Institute of Pathology, University of Würzburg
- Leo Rasche
- Department of Internal Medicine II, University Hospital Würzburg
- Michael Hudecek
- Department of Internal Medicine II, University Hospital Würzburg
- Markus Sauer
- Department of Biotechnology and Biophysics, Biocenter, University of Würzburg
- Jürgen Groll
- Department of Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg
- Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg
- Sabrina Kraus
- Department of Internal Medicine II, University Hospital Würzburg
- Martin K. Kortüm
- Department of Internal Medicine II, University Hospital Würzburg
- DOI
- https://doi.org/10.1038/s42003-021-02215-w
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 14
Abstract
Garitano-Trojaola et al. used a combination of human acute myeloid leukemia (AML) cell lines and primary samples to show that RAC1-dependent actin cytoskeleton remodeling through BCL2 family plays a key role in resistance to the FLT3 inhibitor, Midostaurin in AML. They showed that by targeting RAC1 and BCL2, Midostaurin resistance was diminished, which potentially paves the way for an innovate treatment approach for FLT3 mutant AML.
